Description: NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Home Page: www.neogenomics.com
9490 NeoGenomics Way
Fort Myers,
FL
33912
United States
Phone:
239 768 0600
Officers
| Name | Title |
|---|---|
| Mr. Christopher Michael Smith BSc | CEO & Director |
| Mr. Jeffrey S. Sherman M.B.A. | Chief Financial Officer |
| Mr. Vishal Sikri | President of Advanced Diagnostics |
| Ms. Melody Harris Esq., J.D. | President & COO of Informatics |
| Mr. Warren Stone | Chief Commercial Officer |
| Mr. Gregory D. Aunan | Chief Accounting Officer |
| Ms. Kendra Sweeney | Vice President of Investor Relations & Communications |
| Ms. Alicia Olivo | Executive VP of Business Development, General Counsel & Corporate Secretary |
| Mr. Hutan Hashemi J.D. | Chief Compliance Officer |
| Dr. Derek Lyle M.D. | Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 250 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3339 |
| Price-to-Sales TTM: | 3.2588 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2100 |